In patients with type 2 diabetes or HF, SGLT2 inhibitors reduce gout-related outcomes

Katarzyna Nabrdalik; Professor Gregory Lip

doi:10.7326/j23-0081

Related publications

Article2023

The influence of SGLT2 inhibitors on oxidative stress in heart failure and chronic kidney disease in patients with type 2 diabetes

Diana Nabrdalik-Leśniak, Katarzyna Nabrdalik, Krzysztof Irlik, Oliwia Janota, Hanna Kwiendacz, Paulina Szromek‐Białek, Mirosław Maziarz, Tomasz Stompór, Janusz Gumprecht, Professor Gregory Lip

Article2017

Serum uric acid levels and multiple health outcomes: umbrella review of evidence from observational studies, randomised controlled trials, and Mendelian randomisation studies

Xue Li, Xiangrui Meng, Maria Timofeeva, Ioanna Tzoulaki, Konstantinos K. Tsilidis, John P A Ioannidis, Harry Campbell, Evropi Τheodoratou

Article2024

SGLT2 Inhibitors, but Not GLP-1 Receptor Agonists, Reduce Incidence of Gout in People Living With Type 2 Diabetes Across the Therapeutic Spectrum

Frank Preston, Matthew Anson, David R. Riley, Gema Hernández, Alexander Henney, Professor Gregory Lip, Daniel J. Cuthbertson, Uazman Alam, Sizheng Steven Zhao

Article2021

Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: a systematic review and meta-analysis

Nan Zhang, Yueying Wang, Gary Tse, Panagiotis Korantzopoulos, Κonstantinos P. Letsas, Qingpeng Zhang, Guangping Li, Professor Gregory Lip, Tong Liu

Article2022

Hypertension management in patients with cardiovascular comorbidities

Lucas Lauder, Felix Mahfoud, Michel Azizi, Deepak L. Bhatt, Sebastian Ewen, Kazuomi Kario, Gianfranco Parati, Patrick Rossignol, Markus P. Schlaich, Koon Teo, Raymond R. Townsend, Costas Tsioufis, Michael A. Weber, Thomas Weber, Michael Böhm